Podcasts about frcp

Are deposition expenses busting your budget? In this episode, Jim Garrity spotlights a clever strategy conceived by a southern California litigator to sharply cut the costs of deposition transcripts. It's yet another effort by trial lawyers to combat the insane costs of stenographic reporting, and one worth trying. The show notes point to seventeen relevant filings on this issue, four federal rules, and a website for a service that is actively helping lawyers cut deposition costs.Like this podcast? Our production crew LOVES 5-star reviews. They're free, fast to leave, and provide us the kind of appreciative good vibes we crave. Would you mind taking ten seconds and clicking on the five-star rating? Thanks!SHOW NOTES:Note: All filings listed below are from the case Black v. City of San Diego, Case No. 21-cv-1990-RBM-JLB (S.D. Cal. Mar. 27, 2025)Plaintiff's Application For Leave To Conduct Deposition By Video And To Prepare Transcript Using Voice Recognition Technology According To FRCP Rule 30(b)(3)(A) (initial application by Plaintiff) PACER Doc. 153Defendants' Opposition To Plaintiffs Application For Leave To Prepare Deposition Transcript Using Voice Recognition Technology, PACER Doc. 160.Declaration Of Casey Stark In Support Of Plaintiffs Motion For Leave To Conduct Deposition By Video And To Prepare Transcript Using Voice Recognition Technology According To FRCP 30(b)(3)(A), PACER DOC. 153-1Defendant Tutterow's Notice Of Joinder In Defendant City Of San Diego's Opposition To Plaintiffs Ex Parte Application For Leave To Conduct Deposition By Video And Prepare Transcript Using Voice Recognition, PACER Doc. 162.Defendants Supplement To Opposition To Plaintiffs Application For Leave To Prepare Deposition Transcript Using Voice Recognition Technology, PACER Doc. 164Plaintiffs Reply To Opposition To Application For Leave To Conduct Deposition By Video And To Prepare Transcript Using Voice Recognition Technology According To FRCP Rule 30(b)(3)(A), PACER Doc. 165Second Supplemental Declaration Of Casey Stark In Support Of Plaintiff Motion For Leave To Conduct Deposition. Etc., PACER Doc. 170Defendants Second Supplement To Opposition To Plaintiffs Application For Leave To Prepare Deposition Transcript Using Voice Recognition Technology, PACER Doc. 171Order (Magistrate Judge) Denying Plaintiff's Application For Leave To Conduct Deposition By Video And To Prepare Transcript Using Voice Recognition Technology, PACER Doc. 172Plaintiff's Notice Of Objection To Order Denying Application For Leave To Conduct Deposition, Etc. PACER Doc. 173 (appealing magistrate judge's order to district judge)Defendant's Response To Plaintiff's Objection To Magistrate's Order Denying Claims Application For Leave, PACER Doc. 174Plaintiffs Opposition To Defendants Response To Player's Objection To Magistrate's Order Denying Plaintiff's Application, Etc., PACER Doc. 175Order (District Judge) Overruling Plaintiff's Objections, PACER Doc. 178Order Granting Joint Motion For Protective Order, PACER Doc. 32 (providing that certain information was to remain confidential)Modified Protective Order, PACER Doc. 156Readback.legal (reporting agency dedicated to reducing deposition -related costs; interview of Readback's Chief Legal Officer in podcast episode 87)1993 Committee Note to Fed. R. Civ. P. 26 (noting that where a deposition isn't stenographically recorded, transcripts are often later prepared by counsels' own law firmsFed. R. Civ. P. 30(b)(3)(a) (allowing lawyers to capture deposition testimony by stenographic means only, audio only, video only, or any combination of the three)FRCP 26(a)(3)(A)(ii) and FRCP 32(c) (providing that if counsel chooses to record a deposition by video only and plan to present it at trial or hearing, they must provide a transcript of the testimony to the other parties and the court)Readback.legal (innovative and budget-friendly service advertised as "certified, court-admissible deposition service built for legal professionals who need clarity, speed, and accuracy, without relying on outdated stenography")

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients

Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients

Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients

Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients

Deepak Chopra explores the inner universe and explains how turning inward connects us to God, higher consciousness, and the boundless intelligence of the cosmos.Today's podcast is brought to you by BetterHelp. Give online therapy a try at betterhelp.com/beherenow and get on your way to being your best self.In this deeply intellectual episode, Deepak Chopra holds a lecture on:Three levels of existence: physical, quantum, non-local domainDefining God as the immeasurable potential of all that was, all that is, all that will beHow we are intrinsically connected to the cosmos and universal intelligenceAccessing the wisdom of the universe by turning inwardExperiencing the divine through our own awareness, identity, and perceptionWays we negotiate with the world and looking at the fight-flight response The four control dramas rooted in childhood behavioral conditioningOur innate ability to be in touch with our inner observer—our soul Understanding that consciousness can evolve Freeing ourself from the past, from the known, and not being victimized by our memoriesInvoking Hindu deities like Ganesh for what they symbolize, their knowledge, their energyNumerous levels of God, the creative response, visionary response, sacred response, and beyond“As is the atom, so is the universe. As is the microcosm, so is the macrocosm. As is the human body, so is the cosmic body. As is the human mind, so is the cosmic mind. If something is inside here, it's everywhere. If it's not here, it's nowhere. You, by going inside, can have access to all the knowledge in the whole universe.” – Deepak ChopraThis episode was originally recorded in 2007About Deepak Chopra:Deepak Chopra MD, FACP, FRCP, is a Consciousness Explorer and a world-renowned pioneer in integrative medicine and personal transformation. Dr. Chopra is co-founder of DeepakChopra.ai, his AI twin and well-being advisor. He also co-founded Cyberhuman.ai, a transformative suite of personalized health and well-being solutions. Dr. Chopra is a Clinical Professor of Family Medicine and Public Health at the University of California, San Diego, and serves as a senior scientist with Gallup Organization. He is also an Honorary Fellow in Medicine at the Royal College of Physicians and Surgeons of Glasgow. He is the author of over 95 books, translated into over forty-three languages, including numerous New York Times bestsellers.For the last thirty years, Dr. Chopra has been at the forefront of the meditation revolution. His mission is to create a more balanced, peaceful, joyful and healthier world. Through his teachings, he guides individuals to embrace their inherent strength, wisdom, and potential for personal and societal transformation. In his latest book, Digital Dharma, Dr. Chopra navigates the balance between technology and expanded awareness, explaining that while AI cannot duplicate human intelligence, it can vastly enhance personal and spiritual growth. Learn more about this book and others HERE. “The old paradigm said that human beings are self-contained; we are all independent. But, the new one says that human beings are focal points in one unified field. Unified means everything. Space, time, energy, information, and matter are all part of the field and we are inseparably connected with the pattern of intelligence and the whole cosmos. We are all a web of relationships.” – Deepak ChopraSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  This month, we're diving in deep on the U.S. approval of lenacapavir for PrEP -- both the promise it offers in expanding HIV prevention options and the current uncertainty around access, both in the U.S. and abroad. We also discuss growing concern within the HIV clinical community that our gold-standard guidelines for HIV treatment, care, and prevention may be rousted loose from their long-standing home within the Office of AIDS Research at the U.S. National Institutes of Health. And Laura Waters shares what she's most eager to learn about at IAS 2025, the global HIV science meeting that is taking place as this episode drops.   Please support our podcast by visiting the transcript, which includes links to the many references we mention in this episode: https://www.thebodypro.com/podcast/hiv/future-hiv-care-lenacapavir-prep-guidelines-july-2025   The podfolx: Our co-hosts are Laura Waters, M.D., FRCP, and Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

When Kenisha Hanson was diagnosed with Stage 4 Hodgkin's Lymphoma, her life plans came to a sudden halt. In this episode, Kenisha shares how she redefined success on her own terms and found peace after cancer, alongside reflections from her book Peace Your Way to Success. Joining the conversation is Sandra Turner, nurse coordinator of the PYNK program at Juravinski Cancer Centre, which provides specialized support for young adults diagnosed with breast cancer. Dr. Evans explores the unique challenges faced by young people with cancer navigating fertility, relationships, body image, finances, mental health, and the importance of having the right supports in place.DisclaimerThe Cancer Assist Show is hosted by Dr. Bill Evans, MD, FRCP, Past President of the Juravinski Hospital and Cancer Centre at HHS. Brought to you by the Cancer Assistance Program—an organization lending support to cancer patients and families of those affected by cancer. --- The Cancer Assist Show and its content represent the opinions of Dr. Bill Evans and guests to the podcast. Any views and opinions expressed by Dr. Bill Evans and guests are their own and do not represent those of their places of work. The content of The Cancer Assist Show is provided for informational, educational and entertainment purposes only, and is not intended as professional medical, legal or any other advice, or as a substitute or replacement for any such advice. The Cancer Assist Program, Dr. Bill Evans and guests make no representations or warranties with respect to the accuracy or validity of any information or content offered or provided by The Cancer Assist Show. For any medical needs or concerns, please consult a qualified medical professional. No part of The Cancer Assist Show or its content is intended to establish a doctor-patient or any other professional relationship. This podcast is owned and produced by the Cancer Assistance Program.

Learning Objectives:By the end of this series, listeners should be able to:Understand the research expectations of PICU Fellows in the United States.Explain the types of research available to PICU fellows and how a new fellow might explore their local options. Explain the work necessary to refine a research question and write mature specific aims for a project.  Understand the key factors involved in getting a fellowship paper submitted, including the common pitfalls for each type of research About our Guest: Mike Spaeder is a Professor of Pediatrics at the University of Virginia (UVA) School of Medicine and a pediatric critical care physician at the UVA Children's Hospital in Charlottesville, Virginia. He received his bachelor's degree in mathematics from Trinity College and his master's in statistics from George Washington University, where he also received his medical degree. He completed his pediatrics residency at Hasbro Children's Hospital/Brown University and his pediatric critical care fellowship at the Johns Hopkins Hospital. He is now the director of the Pediatric Critical Care fellowship at the UVA Children's Hospital. His research is based at the Center for Advanced Medical Analytics at the University of Virginia, where he focuses on modeling physiologic signatures of illness to identify patients at risk for clinical deterioration. Selected References:Horvat CM, Hamilton MF, Hall MW, McGuire JK, Mink RB Child Health Needs and the Pediatric Critical Care Medicine Workforce: 2020-2040. Pediatrics 2024 Feb 1 153Tasker RC. Writing for PCCM: The 3,000-Word Structured Clinical Research Report. Pediatr Crit Care Med. 2021 Mar 1;22(3):312-317.Sanchez-Pinto, L. Nelson MD, MBI1; Badke, Colleen M. MD, MS1; Pololi, Linda MBBS, FRCP (hon)2. Group Peer Mentoring: A Strategy to Promote Career Development and Improve Well-Being Among Early-Career Faculty in Pediatric Critical Care Medicine. Pediatric Critical Care Medicine ():10.1097/PCC.0000000000003763, May 15, 2025. | DOI: 10.1097/PCC.0000000000003763 Scott K. Radical Candor: Be a Kick-Ass Boss Without Losing Your Humanity. New York: St. Martin's Press; 2017. 1st ed. Equator Guidelines: https://www.equator-network.org/For Authors : Pediatric Critical Care MediQuestions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Learning Objectives:By the end of this series, listeners should be able to:Understand the research expectations of PICU Fellows in the United States.Explain the types of research available to PICU fellows and how a new fellow might explore their local options. Explain the work necessary to refine a research question and write mature specific aims for a project.  Understand the key factors involved in getting a fellowship paper submitted, including the common pitfalls for each type of research About our Guest: Mike Spaeder is a Professor of Pediatrics at the University of Virginia (UVA) School of Medicine and a pediatric critical care physician at the UVA Children's Hospital in Charlottesville, Virginia. He received his bachelor's degree in mathematics from Trinity College and his master's in statistics from George Washington University, where he also received his medical degree. He completed his pediatrics residency at Hasbro Children's Hospital/Brown University and his pediatric critical care fellowship at the Johns Hopkins Hospital. He is now the director of the Pediatric Critical Care fellowship at the UVA Children's Hospital. His research is based at the Center for Advanced Medical Analytics at the University of Virginia, where he focuses on modeling physiologic signatures of illness to identify patients at risk for clinical deterioration. Selected References:Horvat CM, Hamilton MF, Hall MW, McGuire JK, Mink RB Child Health Needs and the Pediatric Critical Care Medicine Workforce: 2020-2040. Pediatrics 2024 Feb 1 153Tasker RC. Writing for PCCM: The 3,000-Word Structured Clinical Research Report. Pediatr Crit Care Med. 2021 Mar 1;22(3):312-317.Sanchez-Pinto, L. Nelson MD, MBI1; Badke, Colleen M. MD, MS1; Pololi, Linda MBBS, FRCP (hon)2. Group Peer Mentoring: A Strategy to Promote Career Development and Improve Well-Being Among Early-Career Faculty in Pediatric Critical Care Medicine. Pediatric Critical Care Medicine ():10.1097/PCC.0000000000003763, May 15, 2025. | DOI: 10.1097/PCC.0000000000003763 Scott K. Radical Candor: Be a Kick-Ass Boss Without Losing Your Humanity. New York: St. Martin's Press; 2017. 1st ed. Equator Guidelines: https://www.equator-network.org/For Authors : Pediatric Critical Care MediQuestions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Despite decades of effort and innovation since the groundbreaking To Err is Human report over 25 years ago, preventable harm in healthcare persists, and violence against healthcare workers continues to rise. With record understaffing, burnout, mandatory overtime, and mounting documentation demands, the pressure to provide safe care has never been higher nor the stakes more urgent. In this first episode of our new series focusing on safety in healthcare, we explore a bold shift toward "total systems safety" with two leaders at the forefront of this movement who know these challenges all too well. Patricia McGaffigan, RN, MS, CPPS, Senior Advisor for Patient and Workforce Safety at the Institute for Healthcare Improvement, and President of the Certification Board for Professionals in Patient Safety, and Donald Berwick, MD, MPP, FRCP, President Emeritus and Senior Fellow at the Institute for Healthcare Improvement, and former Administrator of the Centers for Medicare and Medicaid Services. Together, they continue to shape national safety efforts including IHI's Safer Together: National Action Plan to Advance Patient Safety the first public-private collaboration of its kind. Spearheaded by McGaffigan and bringing together 27 major organizations that had never collaborated before. The plan aims to restructure the very foundation of healthcare, building safety into every level of the system around four interlocking pillars. Leadership & Governance: Strong, visible leadership and policies that make safety a strategic priority. Workforce Safety & Well-Being: Protecting nurses and healthcare workers – physically and mentally – so they can care safely for others. Patient & Family Engagement: Partnering with patients and family caregivers as co-designers of safe care. Learning Systems: Creating feedback loops and continuous improvement so lessons from one hospital spread everywhere.   At the heart of this movement is a truth long understood by nurses: safety is not a checklist or a policy, it's a culture, a commitment, and a collective responsibility. As Patricia McGaffigan reminds us, “You can't have patient safety if you don't have a safe workforce.” And as Don Berwick warns, “The illusion that safety is a matter of individual effort is one of the most toxic notions in the whole safety enterprise. It is we, not me.” Nurses have always led by example, holding space for healing while navigating broken systems. Now, their leadership is essential in building the future of healthcare safety: one that protects not only patients, but the people who care for them. Where healthcare is not only safer, but also is a culture that ensures we're all Safer Together.

In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:Disease concerns and frequently asked questions from a patient perspectiveManaging symptomsTreatment options and supportive careImportance of awareness and educationPresenters:Gideon Hirschfield, MA, MB BChir, FRCP, PhDLily and Terry Horner Chair in Autoimmune Liver Disease ResearchProfessor, Division of Gastroenterology and HepatologyUniversity of TorontoDirector, The Autoimmune and Rare Liver Disease ProgrammeDirector, Francis Family Liver ClinicToronto General Hospital, University Health NetworkOntario, CanadaJess N. Schnur, BSN-RNNational PBC Patient AdvocateAmerican Liver FoundationDonation Support Services CoordinatorLifeline of OhioColumbus, OhioTo learn more, see the programHear Me: Patient Perspectives on PBC

This month, we're digging into some recent, clinically notable HIV research in the U.S. that leaves us seeing a complex mix of clouds and silver (or perhaps gold?) linings. Specifically: new findings on ART prescription practices; a study on barriers to rapid HIV treatment initiation; and state-level data on PrEP prescribing trends relative to HIV diagnoses.   Support us by visiting the online transcript: https://www.thebodypro.com/podcast/hiv/future-hiv-care-clouds-silver-linings-june-2025   And watch this touching video from Oslo Pride on the importance of symbols: https://www.youtube.com/watch?v=UVepoXddTW4   The pod production team: Our co-hosts are Laura Waters, M.D., FRCP, and Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

Peter Schmid, FRCP, MD, PhD - Use of Neoadjuvant Chemoimmunotherapy Followed by Adjuvant Immunotherapy in Early-Stage TNBC: A Case-Based Discussion

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

In a time of growing uncertainty for the HIV response within the U.S., you may be wondering: What do I do if the public guidelines and resources I rely on to provide HIV-related clinical services cease receiving updates or are permanently removed? Laura and Myles discuss the complexities of our current moment -- and the extent to which our colleagues across the pond in the British HIV Association (BHIVA) can help fill the gap. Laura will also review recent highlights from BHIVA's annual Spring Conference, a cross-disciplinary meeting featuring clinical research and state-of-the-art updates. ° Read the full transcript, which includes a bevy of relevant links: https://www.thebodypro.com/podcast/hiv/future-hiv-care-bhiva-may-2025 ° The pod production team: Our co-hosts are Laura Waters, M.D., FRCP, and Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

Chronicling her dual professional life as a highly respected, Lancet-published academic physician while also investigating powerful psychic and paranormal experiences in her work and personal life, Dr. Blackwell presents compelling evidence for telepathy, clairvoyance, near-death experiences (NDEs), life after death, the power of prayer, non-ordinary reality, and more.The book reveals how, after years of attempting to reconcile her extraordinary experiences, Dr. Blackwell transformed from a scientifically trained medic into a mystic, acknowledging there is far more to life - and to us - than science alone can explain. Her irreverent sense of humour (her account of meeting Prince Charles is unmissable) and her ability to integrate both orthodox and complementary medical practices create a thought-provoking, multi-layered, and often amusing read.By sharing her forays into non-ordinary reality, Dr. Blackwell encourages others to share their paranormal experiences without fear of being labelled ‘crazy'.BioFrom humble beginnings as the daughter of a bus driver and market gardener, growing up on a smallholding in rural Wales, Dr. Blackwell, BSc, AKC, FRCP, rose to become a leading authority in genito-urinary medicine. Immersed in orthodox medicine by day, she devoted her after-hours to the in-depth investigation of anomalous phenomena, energy healing, and metaphysics. Her innate psychic abilities offered profound insights into her patients' lives, psyches, and hidden traumas – insights that few modern doctors are privileged to experience.A passionate explorer of the natural world, with a deep-rooted interest in organic gardening, sustainable living and the mysteries of the cosmos, with years of experience in both scientific research and metaphysical studies, Dr. Blackwell shares her unique perspectives and knowledge through engaging blog posts. Her mission is to inspire others to appreciate the wonders of our universe, from the soil beneath our feet to the stars above. You can read more fascinating stories about her own and others' experiences at Dr Blackwell's website, where she encourages those who have had similar experiences to share them with her audience.https://www.amazon.com/dp/B0DV9KZSY5https://www.drblackwell.co.uk/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP

Chronicling her dual professional life as a highly respected, Lancet-published academic physician while also investigating powerful psychic and paranormal experiences in her work and personal life, Dr. Blackwell presents compelling evidence for telepathy, clairvoyance, near-death experiences (NDEs), life after death, the power of prayer, non-ordinary reality, and more.The book reveals how, after years of attempting to reconcile her extraordinary experiences, Dr. Blackwell transformed from a scientifically trained medic into a mystic, acknowledging there is far more to life - and to us - than science alone can explain. Her irreverent sense of humour (her account of meeting Prince Charles is unmissable) and her ability to integrate both orthodox and complementary medical practices create a thought-provoking, multi-layered, and often amusing read.By sharing her forays into non-ordinary reality, Dr. Blackwell encourages others to share their paranormal experiences without fear of being labelled ‘crazy'.BioFrom humble beginnings as the daughter of a bus driver and market gardener, growing up on a smallholding in rural Wales, Dr. Blackwell, BSc, AKC, FRCP, rose to become a leading authority in genito-urinary medicine. Immersed in orthodox medicine by day, she devoted her after-hours to the in-depth investigation of anomalous phenomena, energy healing, and metaphysics. Her innate psychic abilities offered profound insights into her patients' lives, psyches, and hidden traumas – insights that few modern doctors are privileged to experience.A passionate explorer of the natural world, with a deep-rooted interest in organic gardening, sustainable living and the mysteries of the cosmos, with years of experience in both scientific research and metaphysical studies, Dr. Blackwell shares her unique perspectives and knowledge through engaging blog posts. Her mission is to inspire others to appreciate the wonders of our universe, from the soil beneath our feet to the stars above. You can read more fascinating stories about her own and others' experiences at Dr Blackwell's website, where she encourages those who have had similar experiences to share them with her audience.https://www.amazon.com/dp/B0DV9KZSY5https://www.drblackwell.co.uk/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP

Myles Helfand and Laura Waters, M.D., FRCP, discuss recently published, clinically noteworthy findings from a trio of venerable HIV cohort studies. First, they review new data from the ATHENA study on non-AIDS events among so-called "HIV controllers." They then move on to recent findings from the START study regarding the link between ART initiation timing and cardiovascular disease risk. Finally, they explore new REPRIEVE data exploring the impact (or lack thereof) of statin use on non-cardiovascular events. ‡ Read (and share!) the full transcript: https://www.thebodypro.com/hiv/future-hiv-care-nuances-matter-april-2025 ‡ The pod production team: Our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

In this episode, Chloe Orkin, MBChB, FRCP, MD, and Jean-Michel Molina, MD, PhD, discuss highlights from CCO's independent conference coverage of CROI 2025, including:Advances in HIV treatment based on results from CARESPotential HIV therapies in the pipeline, such as doravirine/islatravirEffects of broadly neutralizing antibodies on HIV treatment and cure Key clinical data on HIV and STI prevention obtained from PILLAR, HPTN 083, PURPOSE 1, and STOMPPresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationHonorary Consultant Physician, Barts Health NHS TrustFaculty of Medicine and DentistryQueen Mary University of LondonLondon, United KingdomJean-Michel Molina, MD, PhDProfessor of MedicineUniversity of Paris CiteDepartment of Infectious DiseasesSaint-Louis and Lariboisiere Hospitals, APHPParis, FranceLink to full program:bit.ly/3E1bAYQTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.During their conversation, Dr. Morice and Dr. Tan explore:Inspiration for developing the liquid biopsy.Features that differentiate LiquidHALLMARK® from existing cancer tests.Patients who will benefit from the test and how an oncologist might use the results.The future potential of liquid biopsy advancements.

In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:Disease concerns and frequently asked questions from a patient perspectiveManaging symptomsTreatment options and supportive careImportance of awareness and educationPresenters:Gideon Hirschfield, MA, MB BChir, FRCP, PhDLily and Terry Horner Chair in Autoimmune Liver Disease ResearchProfessor, Division of Gastroenterology and HepatologyUniversity of TorontoDirector, The Autoimmune and Rare Liver Disease ProgrammeDirector, Francis Family Liver ClinicToronto General Hospital, University Health NetworkOntario, CanadaJess N. Schnur, BSN-RNNational PBC Patient AdvocateAmerican Liver FoundationDonation Support Services CoordinatorLifeline of OhioColumbus, OhioTo learn more, see the program Hear Me: Patient Perspectives on PBC

In this episode, Jim Garrity spotlights a new ruling on a little-known but powerful tool: the use of depositions as affidavits. As Garrity discusses, a deposition does not need to meet the requirements of trial-oriented Fed. R. Civ. P. 32 (which requires a showing that the party against whom the deposition is offered had notice and a chance to examine the deposition) when it is offered in proceedings that allow testimony by affidavit, such as at summary judgment.SHOW NOTESSurety v. Co. v. Dwight A. Herald, et al., Case No. 1:23-cv-00086-GNS-HBB, 2025 WL 627523 (W.D. Ky. Feb. 26, 2025) (deposition/examination under oath of witness taken in underlying state-court personal injury could be used in federal declaratory judgment actions at summary judgment time, as deposition meets form of affidavit)Diamonds Plus, Inc. v. Kolber, et al., 960 F. 2d 765 (8th Cir. 1992) (deposition need not be admissible at trial to be properly considered in opposition to motions for summary judgment; deposition inadmissible at trial because one of the defendants did not receive proper notice and did not attend the deposition was properly used to create issues of fact justifying denial of summary judgment)Hoover v. Switlik Parachute Co., 663 F.2d 964, 966-67 (9th Cir. 1981) (“Rule 56 ... plainly allows consideration of “affidavits” and we find nothing which requires that term to be construed within the limitations of Rule 32(a).”).First Gaston Bank of North Carolina v. City of Hickory, 691 S.E.2d 715 (Ct. App. N.C. 2010) (citing cases rejecting proposition that FRCP 32 limits use of depositions in proceedings where evidence in affidavit form is admissible; pointing out that to the extent a party objects that they didn't have an opportunity to cross-examine a witness whose deposition from some other cases being offered, “the same objection can frequently be made as to affidavits filed in connection with motions for summary judgment”)Tingey v. Radionics, 193 F. App'x 747, 765–66 (10th Cir. 2006) (reversing summary judgment where trial court, relying on FRCP 32, excluded from consideration in opposition to summary judgment a deposition that plaintiff took of physician in separate state proceeding, where defendant was not party to that proceeding and had not been given notice of deposition; depositions can be used as affidavits in proceedings where affidavits are admissible; to illustrate, “[p]arties may file affidavits in support of summary judgment without providing notice or an opportunity to cross-examine the affiant. See Fed.R.Civ.P. 56(c). The “remedy” for this non-confronted affidavit testimony is to file an opposing affidavit, not to complain that one was not present and permitted to cross-examine when the affidavit was signed. For this reason, the Ninth Circuit has permitted a party to introduce deposition testimony for summary judgment purposes against a party who was not present at the deposition, by construing the deposition as an affidavit. Hoover v. Switlik Parachute Co., 663 F.2d 964, 966–67 (9th Cir.1981)”)Nippon Credit Bank, Ltd. v. Matthews, 291 F.3d 738, 751 (11th Cir. 2002) (without analyzing scope and extent of application of FRCP 32, court broadly said that “Depositions are generally admissible provided that the party against whom they are admitted was present, represented, or reasonably noticed, Fed.R.Civ.P. 32(a), and are specifically allowed in consideration of summary judgment. Fed.R.Civ.P. 56(c). A deposition taken in a different proceeding is admissible if the party against whom it is offered was provided with an opportunity to examine the deponent. Fed.R.Evid. 804(b)(1).”)Fed. R. Civ. P. 56(c)(1)(A) (explicitly allowing citation to depositions for or against summary judgment)8 Charles Alan Wright & Arthur R. Miller, Federal Practice and Procedure § 2142 (1970))) (as are at least as good as affidavits and should be usable whenever an affidavit would be permissible, even where the conditions or requirements for use at trial under rule 32 are not met)